Your browser doesn't support javascript.
loading
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.
Xie, Congying; Jing, Zhao; Luo, Honglei; Jiang, Wei; Ma, Li; Hu, Wei; Zheng, Anping; Li, Duojie; Ding, Lingyu; Zhang, Hongyan; Xie, Conghua; Lian, Xilong; Du, Dexi; Chen, Ming; Bian, Xiuhua; Tan, Bangxian; Xia, Bing; Xie, Ruifei; Liu, Qing; Wang, Lvhua; Wu, Shixiu.
Afiliação
  • Xie C; Department of Radiation and Medical Oncology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Jing Z; Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, China.
  • Luo H; Department of Radiation Oncology, No. 1 People's Hospital of Huaian, Huaian, China.
  • Jiang W; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
  • Ma L; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
  • Hu W; Department of Radiation Oncology, Taizhou Hospital of Zhejiang Province, Linhai, China.
  • Zheng A; Department of Radiation Oncology, Anyang Cancer Hospital, Anyang, China.
  • Li D; Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Ding L; Department of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou, China.
  • Zhang H; Department of Radiation Oncology, Anhui Provincial Hospital, Anhui, China.
  • Xie C; Department of Radiation Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Lian X; Department of Radiation Oncology, Kaohsiung Medical University Hospital Cancer Centre, Kaohsiung, Taiwan.
  • Du D; Department of Radiation Oncology, Central Hospital of Lishui City, Lishui, China.
  • Chen M; Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Bian X; Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, China.
  • Tan B; Department of Radiation Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
  • Xia B; Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, China.
  • Xie R; Department of Biostatistics, Hangzhou Cancer Hospital, Hangzhou, China.
  • Liu Q; Department of Biostatistics, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Wang L; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. wlhwq@yahoo.com.
  • Wu S; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. wushixiu@medmail.com.cn.
Br J Cancer ; 123(11): 1616-1624, 2020 11.
Article em En | MEDLINE | ID: mdl-32958820
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Quimiorradioterapia / Cloridrato de Erlotinib / Carcinoma de Células Escamosas do Esôfago Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Quimiorradioterapia / Cloridrato de Erlotinib / Carcinoma de Células Escamosas do Esôfago Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China